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Abstract
Background: To evaluate the cardioprotective effects of sevoflurane versus propofol anesthesia in patients
undergoing cardiac surgery.
Methods: Studies were retrieved through searching several databases. Study quality was evaluated by Jadad scale.
Meta-analysis was performed with RevMan5.0 software. Publication bias was tested by funnel plot.
Results: As a result, 15 studies were included. Compared with propofol, sevoflurane anesthesia significantly
improved postoperative (WMD (weighted mean difference) = 0.62, 95% CI: 0.33 to 0.92; P < 0.0001) and
postoperative 12 hour cardiac index (WMD = 0.18, 95% CI: 0.03 to 0.33; P = 0.02), postoperative cardiac output
(WMD = 1.14, 95% CI: 0.74 to 1.54; P < 0.00001), and reduced postoperative 24 hour cardiac troponin I
concentration (WMD = -0.86, 95% CI:-1.49 to -0.22; P = 0.008), postoperative inotropic drug usage (OR
(odds ratio) = 0.31, 95% CI: 0.22 to 0.44; P < 0.00001), vasoconstrictor drug usage (OR = 0.30, 95% CI:0.21 to 0.43; P
< 0.00001), ICU stay (WMD = -15.53, 95% CI: -24.29 to -6.58; P = 0.0007) and a trial fibrillation incidence (OR = 0.25,
95% CI: 0.07 to 0.85; P = 0.03). However, no significant differences were found in other indexes. Subgroup analysis
indicated the similar results.
Discussion: The sevoflurane-induced cTnI reduction is associated with lower incidence of late adverse cardiac
events, accounting for its roles in cardiac protection. Several limitations existed such as the small sample size and
the lack use of blind design.
Conclusions: Sevoflurane may exhibit a more favorable cardioprotective effect during cardiac surgery than
propofol.
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Background
Myocardial injury is a common complication in patients
undergoing cardiac surgery, which can result in delayed
recovery, organ failure, increased hospital length of stay,
and mortality [1, 2]. To protect the myocardium from
injury related to cardiac surgery, several approaches have
been postulated, such as inhalation anesthetic precondi-
tioning [3].
Volatile anesthetics have been suggested to contribute
to myocardial protection through a preconditioning
effect on the myocardium. The mechanisms involved in
the protective effect of volatile anesthetic regimens are
opening of mitochondrial KATP channels, activation of
p38 mitogen-activated protein kinase, and an increase in
mitochondrial reactive oxygen species. All these mecha-
nisms account for decreased cytosolic and mitochondrial
calcium loading [4–6]. A meta-analysis showed that
volatile anesthetics, including sevoflurane, have benefi-
cial effects on reducing morbidity and mortality, and
thus play a cardioprotective effect on patients after car-
diac surgery [7]. Intravenous anesthetics, such as propo-
fol, are also reported to have a cardioprotective effect.
This includes markedly decreasing the size of myocardial
infarcts, lowering troponin release, and decreasing the
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rate of mortality after cardiac surgery [6, 8, 9]. A more
recent study provided evidence that sevoflurane provides
slightly better protection of the mitochondrial outer
membrane than propofol in patients undergoing coron-
ary artery bypass grafting (CABG) surgery with cardio-
pulmonary bypass [10]. However, which anesthetic is
more favorable after cardiac surgery is controversial
[11–13]. Recently published studies might provide
additional information about the clinical outcomes of
sevoflurane and propofol. Therefore, the two drugs’ car-
dioprotective effect on patients should be re-evaluated
using powerful statistical analysis tools. Therefore, we
performed a meta-analysis to compare the cardioprotec-
tive effects of sevoflurane and propofol on patients
undergoing cardiac surgery. This information could pro-




We applied the PRISMA guidelines for the reporting of
systematic reviews and meta-analyses to carry out this
meta-analysis [14].
We retrieved literature on the effects of sevoflurane or
propofol on myocardial protection by searching MED-
LINE, the Cochrane Library, and EMBASE databases
from their inception to June 2014. We supplemented
this work with manual searches and reference backtrack-
ing. The keywords that were used for searching were
“sevoflurane”, “propofol”, “total intravenous anesthesia”,
“cardiac surgery”, “cardioprotection”, and “randomized
controlled clinical trials”.
Inclusion criteria
The following inclusion criteria were used for potentially
relevant studies: (1) the participants in a study were
adult patients undergoing cardiac surgery; (2) the study
was a prospective, randomized, controlled clinical trial;
(3) for anesthesia treatments in which the experimental
group was anesthetized using sevoflurane, no propofol
was used throughout the entire anesthesia process (in-
cluding induction and maintenance phase), while the
control group was anesthetized using propofol and no
sevoflurane was used during the entire anesthesia
process; (4) the study comprised detailed information,
such as the number of cases, the number of controls,
and the number of completed trials; and (5) the study
involved measurement indices, including the postopera-
tive cardiac index (CI), cardiac output (CO), postopera-
tive cardiac troponin I (cTnI), postoperative mechanical
ventilation time, intensive care unit (ICU) observation
time, hospital stay, postoperative inotropic and vasocon-
strictor drugs, postoperative atrial fibrillation, and myo-
cardial infarction.
Data extraction and quality assessment
Based on the predefined standard form, we abstracted
the following information: the number of cases, type of
anesthetic, dose of anesthetic, anesthetic method, and
measurement indices.
The Jadad scale [15] evaluation system was used to as-
sess the quality of the identified literature, based on study
design, interventions, and measurement indices. Two
researchers performed the evaluation independently.
Disagreement was resolved through discussion with a
third investigator. Any study with a Jadad score ≥ 3 was
regarded as high quality.
Statistical analysis
Review Manager (RevMan) Version 5.0 (Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collabor-
ation, 2014) software was used for meta-analysis and for-
est plots. The weighted mean difference (WMD) with
the corresponding 95 % confidence interval (CI) was cal-
culated as the effect size for estimating numerical vari-
ables, while odds ratios (ORs) with 95 % CIs were used
for dichotomous variables. The chi-square test and I2 stat-
istic were performed to determine heterogeneity among
studies. If significant homogeneity existed (P > 0.1 and
I2 < 50 %), a fixed effects model was used to calculate
the pooled WMD or OR. A random effects model was
used if P < 0.1 and I2 > 50 %. Subgroup analysis was per-
formed, stratified either by the type of cardiac surgery
(CABG or aortic valve replacement [AVR]) or use of
cardiopulmonary blood bypass during CABG (on-pump
or off-pump).
Publication bias
Publication bias detection was conducted through
symmetry of funnel plots that were generated by Rev-
Man 5.0.
Sensitivity analysis
Sensitivity analysis was performed by calculating the
pooled effect size after removing studies one at a time to




Duplicated publications were removed and studies that
did not involve comparison of propofol and sevoflurane
were excluded. If a cohort of studies was published
based on one data set, the study that had the most com-
prehensive data was included for the meta-analysis. As a
result, a total of 113 studies were obtained through pre-
liminary screening. Ten reviews were then excluded by
browsing the title and reading the abstract. Next, 38 case
reports and 33 observational studies were eliminated
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through further selection. From the remaining 32 stud-
ies, 17 retrospective studies and non-randomized clinical
studies were removed after full text reading. Finally, 15
eligible studies [16–30] were included for the meta-
analysis. A flow chart of the literature selection is shown
in Fig. 1.
Characteristics of the eligible studies and quality
assessment
The characteristics of the included studies are shown in
Table 1. A total of 1646 participants (1094 in the experi-
mental group and 552 in the control group) were in-
volved in the studies. All of the studies were published
in English and they were carried out in 11 countries or
regions. An assessment of quality is shown in Table 2.
Because of the large proportion of high-quality research
(3 studies with a score of 5, 1 study with score of 4, 3
studies with a score of 3, 5 studies with a score of 2, and
3 studies with a score of 1), the overall quality of the in-
cluded studies was relatively high.
Outcome of the effect of sevoflurane and propofol on
cardioprotection
CI
Six studies involved the postoperative CI. A random ef-
fects model was adopted because remarkable heterogen-
eity existed across studies (P < 0.001, I2 = 83 %). The
sevoflurane group showed a significantly higher postop-
erative CI than the propofol group (WMD = 0.62, 95 %
CI: 0.33 to 0.92; P < 0.001) (Fig. 2a). Subgroup analysis
showed that a higher postoperative CI was observed in
the on-pump CABG subgroup (WMD= 0.63, 95 % CI:
0.24 to 1.03; P < 0.001) and off-pump CABG subgroup
(WMD = 0.57, 95 % CI: 0.19 to 0.95; P = 0.003).
Five studies described the postoperative 12-h CI. A
fixed effects model was used because there was no
between-study heterogeneity (P = 0.70, I2 = 0 %). The
postoperative 12-h CI of the sevoflurane group was
significantly higher than that of the propofol group
(WMD = 0.18, 95 % CI: 0.03 to 0.33; P = 0.02) (Fig. 2b).
A similar conclusion was obtained in the on-pump
CABG subgroup (WMD = 0.21, 95 % CI: 0.05 to 0.36;
P = 0.008), but not in the off-pump CABG subgroup
(WMD = −0.20, 95 % CI: −0.76 to 0.36; P = 0.49).
Cardiac output
Three studies provided CO. A random effects model was
used for detection of substantial heterogeneity (P = 0.08,
I2 = 61 %). As shown in Fig. 3a, CO of the sevoflurane
group was significantly higher than that of the propofol
group (WMD= 1.14, 95 % CI: 0.74 to 1.54; P < 0.001).
Three studies provided postoperative 12-h CO. A ran-
dom effects model was used because there was between-
study heterogeneity (P < 0.001, I2 = 92 %). No significant
difference in postoperative 12-h CO was found between
the sevoflurane group and the propofol group (WMD=
0.38, 95 % CI: −0.26 to 1.01; P = 0.24) (Fig. 3b).
cTnI
cTnI is an indicator of postoperative myocardial injury.
Three studies provided postoperative 24-h cTnI data.
Three types of surgical procedures that were used were
on-pump CABG, off-pump CABG, and AVR. A fixed
effects model was applied for the absence of heterogen-
eity across studies (P = 0.26, I2 = 27 %). As a result,
sevoflurane showed significantly lower postoperative
24-h cTnI levels compared with propofol treatment
(WMD = −0.86, 95 % CI: −1.49 to −0.22; P = 0.008)
(Fig. 4).
Mechanical ventilation time
Three studies reported postoperative mechanical ventila-
tion time. A random effects model was used because of
remarkable heterogeneity (P = 0.01, I2 = 77 %). There was
no significant difference between the sevoflurane and
propofol groups (WMD = −0.80, 95 % CI: −1.71 to 0.11;
P = 0.08) (Fig. 5). Subgroup analysis showed that the
mechanical ventilation time of the sevoflurane group
was significantly shorter than that of the propofol group
in the on-pump CABG subgroup (WMD = −1.03, 95 %
CI: −1.81 to −0.25; P = 0.010). However, no significant
difference was observed in the AVR subgroup (WMD =
1.64, 95 % CI: −1.23 to 4.51; P = 0.26).
Drug use
Six studies reported postoperative inotropic drug use
data. A fixed effects model was adopted there was no
heterogeneity between studies (P = 0.66, I2 = 0 %). Ino-
tropic drug use of the sevoflurane group was signifi-
cantly less than that of the propofol group (OR = 0.31,
95 % CI: 0.22 to 0.44; P <0.001) (Fig. 6a). A similar
Fig. 1 Flow chart of literature selection
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Table 1 Basic Information of the 15 studies included in the meta-analysis




Sevoflurane group Propofol group
Induction Maintenance Induction Maintenance
Gravel et al. [10] Canada CABG (on-pump and
off-pump)




1 mg midazolam +
0.5 μg/kg sufentanil
40-150 μg/kg/min
propofol + 0.5 μg/kg/h
sufentanil
De Hert et al. [11] Belgium CABG (on-pump) 10/10 4 % sevoflurane +
0.4 μg/kg/min remifentanil
0.5–2 % sevoflurane +
0.3–0.6 μg/kg/min
remifentanil
2 mg/ml propofol +
0.4 μg/kg/min remifentanil
2-4 mg/ml propofol +
0.3-0.6 μg/kg/min
remifentanil
Conzen et al. [12] Germany CABG (off-pump) 10/10 0.3 mg/kg etomidate 2 % sevoflurane 2 μg/ml propofol 2-3 μg/ml propofol





2 μg/ml propofol +
0.4 μg/kg/min remifentanil
2-4 μg/ml propofol +
0.3-0.6 μg/kg/min
remifentanil
De Hert et al. [14] Belgium CABG (on-pump) 80/80 0.1 mg/kg midazolam +
0.4 μg/kg/min remifentanil





2-4 μg/ml propofol +
0.2-0.4 μg/kg/min
remifentanil
Parker et al. [15] Australia CABG (on-pump) 118/118 10 μg/kg fentanyl +
0.1 mg/kg diazepam +
0.15 mg/kg pancuronium
bromide
1–4 % sevoflurane 10 μg/kg fentanyl + 0.1 mg/kg
diazepam + 0.15 mg/kg
pancuronium bromide
1-8 μg/ml propofol
Kawamura et al. [16] Japan CABG (on-pump) 13/10 10 μg/kg fentanyl + 2–3 mg
midazolam
0.5 %-1 % sevoflurane +
30 μg/kg fentanyl
10 μg/kg fentanyl + 2–3 mg
midazolam
2-8 mg/kg/h propofol +
30 μg/kg fentanyl
Cromheecke et al. [17] Belgium AVR 15/15 0.5–1 % sevoflurane +
0.4 μg/kg/min remifentanil
0.5–1 % sevoflurane +
0.2–0.4 μg/kg/min
remifentanil





Lorsomradee et al.[18] Belgium CABG (on-pump) 160/160 sevoflurane + 0.2–0.4 μg/kg/min
remifentanil
0.5–2 % sevoflurane +
0.2–0.4 μg/kg/min
remifentanil
2 μg/ml propofol +
0.2-0.4 μg/kg/min remifentanil
2-4 μg/ml propofol +
0.2-0.4 μg/kg/min
remifentanil








Lucchinetti et al. [20] Switzerland CABG (off-pump) 10/10 fentanyl + midazolam sevoflurane + fentanyl +
midazolam
fentanyl + midazolam propofol + fentanyl +
midazolam
Yildirim et al. [21] Turkey CABG (on-pump) 20/20 2–8 % sevoflurane + 0.4 μg/kg/
min remifentanil
0.5–2 % sevoflurane +
0.3–0.6 μg/kg/min
remifentanil





Ballester et al. [22] Spain CABG (off-pump) 18/20 0.1 mg/kg midazolam + 2–4 μg/
kg fentanyl + 0.3 mg/kg
etomidate
1.5–2.5 % sevoflurane 0.1 mg/kg midazolam +
2–4 μg/kg fentanyl +
0.3 mg/kg etomidate
6-8 mg/kg/h propofol




1–1.5 mg/kg propofol +
0.7–1 mcg/kg sufentanil
6-10 mg/kg/h propofol +
0.1-0.2 mcg/kg/h
sufentanil
Suryaprakash et al. [24] India CABG (off-pump) 48/39 5–10 μg/ kg fentanyl + 0.02 mg/
kg midazolam
1–2 % sevoflurane +
1 μg/kg/h fentanyl
5–10 μg/ kg fentanyl +
0.02 mg/kg midazolam
2-4 mg/kg/h propofol +
1 μg/kg/h fentanyl












Table 2 Jadad score of the included studies
Study Random method Blind Exit in follow-up Jadad score
Gravel et al. [10] Yes with description Single No 3
De Hert et al. [11] Yes without description Not described No 2
Conzen et al. [12] Yes without description Not described No 2
De Hert et al. [13] Yes without description Not described Yes with description 2
De Hert et al. [14] Yes with description Double No 5
Parker et al. [15] Yes without description Double Yes with description 4
Kawamura et al. [16] Yes without description Single Not described 1
Cromheecke et al. [17] Yes with description Not described No 3
Lorsomradee et al. [18] Yes with description Double No 5
Law-Koune et al. [19] Yes without description Single Not described 1
Lucchinetti et al. [20] Yes without description Not described Not described 1
Yildirim et al. [21] Yes with description Double No exit 5
Ballester et al. [22] Yes with description Single Yes with description 3
Jovic et al. [23] Yes without description Not described No 2
Suryaprakash [24] Yes with description Not described Not described 2
Fig. 2 Forest plots of the postoperative cardiac index (a) and postoperative 12-h cardiac index (b). Sevoflurane and propofol groups were
compared
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conclusion was obtained in the on-pump CABG sub-
group (OR = 0.32, 95 % CI: 0.22 to 0.45; P < 0.001) and
the AVR subgroup (OR = 0.18, 95 % CI: 0.04 to 0.36; P =
0.03).
Five studies provided inotropic drug use data during
the ICU stay. A fixed effects model was used for the
homogeneity (P = 0.44, I2 = 0 %). Inotropic drug use dur-
ing the ICU stay of the sevoflurane group was signifi-
cantly less than that of the propofol group (OR = 0.30,
95 % CI: 0.21 to 0.43; P < 0.001) (Fig. 6b). A similar con-
clusion was obtained in the on-pump CABG subgroup
(OR = 0.30, 95 % CI: 0.21 to 0.43; P < 0.001), but not in
the AVR subgroup (OR = 0.38, 95 % CI: 0.07 to 1.92; P =
0.24).
Six studies contained information about postoperative
vasoconstrictor drug use. A fixed effects model was ap-
plied for the absence of heterogeneity between studies
(P = 0.63, I2 = 0 %). Postoperative vasoconstrictor drug
use of the sevoflurane group was significantly lower than
that of the propofol group (OR = 0.51, 95 % CI: 0.35 to
0.74; P = 0.0004) (Fig. 6c). A similar conclusion was ob-
tained in the on-pump CABG subgroup (OR = 0.53,
95 % CI: 0.36 to 0.77; P = 0.001), but not in the AVR
subgroup (OR = 0.23, 95 % CI: 0.04 to 1.41; P = 0.11).
Five studies reported information about vasocon-
strictor drug use during the ICU stay. There was no het-
erogeneity between studies (P = 0.63, I2 = 0 %); therefore,
a fixed effects model was applied. Vasoconstrictor drug
Fig. 3 Forest plots of postoperative cardiac output (a) and postoperative 12-h cardiac output (b). Sevoflurane and propofol groups
were compared
Fig. 4 Forest plot showing comparison of postoperative 24-h cTnI between the sevoflurane and propofol groups
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use during the ICU stay of the sevoflurane group was
significantly less than that of the propofol group (OR =
0.51, 95 % CI: 0.35 to 0.72; P = 0.0002) (Fig. 6d). A simi-
lar conclusion was obtained in the on-pump CABG sub-
group (OR = 0.52, 95 % CI: 0.36 to 0.75; P = 0.0004), but
not in the AVR subgroup (OR = 0.32, 95 % CI: 0.07 to
1.47; P = 0.14).
Postoperative ICU length of stay
Four studies involved postoperative length of stay in
the ICU. A random effects model was applied because
of between-study heterogeneity (P = 0.03, I2 = 67 %).
The postoperative ICU length of stay was considerably
lower in the sevoflurane group than in the propofol
group (WMD = −15.53, 95 % CI: −24.29 to −6.58; P =
0.0007) (Fig. 7a). A similar conclusion was obtained in
the on-pump CABG subgroup (WMD = −18.00, 95 %
CI: −25.80 to −10.20; P < 0.001), but not in the other
subgroups.
Five studies reported postoperative hospital stay data.
A random effects model was adopted because of
between-study heterogeneity (P < 0.001, I2 = 85 %). There
was no significant difference in postoperative length of
hospital stay between the two groups (WMD= −1.70,
95 % CI: −4.24 to 0.84; P = 0.19) (Fig. 7b). Subgroup ana-
lysis of the on-pump CABG subgroup showed that the
length of hospital stay of the sevoflurane group was sig-
nificantly shorter than that of the propofol group
(WMD = −4.00, 95 % CI: −5.25 to −2.75; P < 0.001). No
significant difference was found in hospital length of stay
in the other subgroups.
Incidence of postoperative complications and mortality
Eight studies provided information on the incidence of
postoperative myocardial infarction. A fixed effects
model was used for observation of homogeneity (P =
0.59, I2 = 0 %). There was no significant difference in
the incidence of postoperative myocardial infarction
between the sevoflurane and propofol groups (OR =
0.54, 95 % CI: 0.20 to 1.49; P = 0.24) (Fig. 8a). There
was also no significant difference in any of the
subgroups.
Five studies provided the incidence of postoperative
atrial fibrillation. No between-study heterogeneity was
detected (P = 0.57, I2 = 0 %) and a fixed effects model
was used. The incidence of postoperative atrial fibrilla-
tion of the sevoflurane group was significantly lower
than that of the propofol group (OR = 0.25, 95 % CI:
0.07 to 0.85; P = 0.03) (Fig. 8b). No significant difference
was found in any of the subgroups.
Six studies provided postoperative mortality data. A
fixed effects model was used in analysis because there
was no heterogeneity between studies (P = 0.50, I2 =
0 %). There was no significant difference in mortality be-
tween the sevoflurane and propofol groups (OR = 0.73,
95 % CI: 0.14 to 3.78; P = 0.71) (Fig. 8c). Subgroup ana-
lysis showed no significant difference in mortality in any
of the subgroups.
Publication bias and sensitivity analysis
Sensitivity analysis showed that the conclusion was not
affected by exclusion of any single included study. No
obvious publication bias was found according to the fun-
nel plots (Fig. 9).
Discussion
In this study, we retrieved 15 randomized, controlled tri-
als to compare the cardioprotective effect of sevoflurane
with propofol anesthesia in cardiac surgery. We found
that sevoflurane was superior to propofol in the postop-
erative CI, postoperative 24-h CI, postoperative CO,
postoperative 24-h cTnI concentrations, inotropic drug
use, vasoconstrictor drug use, ICU length of stay, and in-
cidence of atrial fibrillation. However, no significant dif-
ference was found in postoperative 12-h CO, mechanical
ventilation time, hospital length of stay, incidence of
Fig. 5 Forest plot showing comparison of mechanical ventilation time between the sevoflurane and propofol groups
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Fig. 6 Forest plot of postoperative inotropic drug use (a). Forest plot of inotropic drug use during the ICU stay (b). Forest plot of postoperative
vasoconstrictor drug use (c). Forest plot of vasoconstrictor drug use during ICU stay (d). Sevoflurane and propofol groups were compared
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myocardial infarction, and mortality between sevoflurane
and propofol. All of these findings were consistent with
a previous meta-analysis, except for inotropic drug use
and the incidence of atrial fibrillation, which showed a
comparable effect [13]. However, subgroup analysis was
not involved in this previous study and the samples were
relatively small. By contrast, our study applied a more
strict inclusion criterion in case and control experimen-
tal design. We focused only on studies in which the ex-
perimental group was anesthetized using sevoflurane but
not propofol throughout the entire anesthesia process,
while the control group was anesthetized by propofol
but not sevoflurane. In Yao and Li’s meta-analysis [13],
the experimental or control group was anesthetized
using both sevoflurane and propofol in some of the in-
cluded studies. Additionally, we carried out subgroup
analysis in our study, which made the results more pre-
cise than previous analyses.
The level of cTnI is a sensitive and specific marker of
myocardial injury. A sevoflurane-induced reduction in
cTnI levels is associated with a lower incidence of late
adverse cardiac events [31]. Accordingly, we observed a
lower incidence of atrial fibrillation in the sevoflurane
group than in the propofol group. ICU and the hospital
stay length are two comprehensive indicators that are as-
sociated with postoperative complications and medical
fees. The current study showed that use of sevoflurane
led to a shorter ICU stay length, but not hospital stay
length compared with the propofol group. This finding
might be explained by different study populations and
varying hospital operating standards. Moreover, reduced
inotropic drug use in the sevoflurane group is consistent
Fig. 7 Forest plots of postoperative ICU length of stay (a) and hospital length of stay (b). Sevoflurane and propofol groups were compared
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Fig. 8 Forest plots of the incidence of postoperative myocardial infarction (a). Forest plot of atrial fibrillation (b). Forest plot of mortality (c).
Sevoflurane and propofol groups were compared
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with the study by Yu et al. [8], which showed that vola-
tile anesthetics benefit myocardial energy stores during
ischemia and subsequent recovery after reperfusion [8].
Volatile anesthetics have a long-lasting cardioprotec-
tive effect that enhances their administration during car-
diac surgery [32]. Extensive studies have confirmed that
sevoflurane protests against ischemic myocardial damage
[32, 33]. However, in our study, no significant difference
was detected in the incidence of postoperative myocar-
dial infarction between sevoflurane and propofol, sug-
gesting that propofol might have comparable myocardial
protection with sevoflurane.
In our meta-analysis, all of the included 15 studies were
prospective, randomized, clinical trials, and their quality
was high. Additionally, we conducted subgroup analysis to
obtain accurate results. However, several limitations
should be mentioned. First, because of language restric-
tions and database updates, we could not include litera-
ture in other languages nor those yet to be published.
Including those studies would have affected our results.
Second, the sample size was small and no blinding was
mentioned in some studies. Third, differences in surgical
and medical technology among the studies included also
affected the results. Finally, significant heterogeneity was
observed in some assessment indices, which might have
caused bias in our results. We assert that more high-
quality, randomized, controlled trials are warranted.
Conclusions
In conclusion, sevoflurane anesthesia has a better cardio-
protective effect on patients undergoing cardiac surgery
according to several indicators than propofol anesthesia.
However, multicenter, prospective, randomized, con-
trolled trails with large samples, uniform criteria, and
surgical procedures are necessary to further confirm the
advantage of sevoflurane over propofol.
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